Neuronetics (NASDAQ:STIM - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08), Zacks reports. The firm had revenue of $31.98 million for the quarter, compared to the consensus estimate of $29.07 million. Neuronetics had a negative return on equity of 141.24% and a negative net margin of 50.09%. Neuronetics updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.
Neuronetics Stock Performance
NASDAQ:STIM traded down $0.22 during trading hours on Friday, reaching $4.43. The stock had a trading volume of 817,650 shares, compared to its average volume of 726,572. The stock has a market cap of $291.56 million, a P/E ratio of -3.60 and a beta of 1.92. The stock has a 50 day simple moving average of $4.25 and a 200 day simple moving average of $2.84. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16. Neuronetics has a 12-month low of $0.52 and a 12-month high of $5.92.
Insider Transactions at Neuronetics
In other news, CFO Stephen Furlong sold 17,307 shares of Neuronetics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $4.11, for a total value of $71,131.77. Following the completion of the transaction, the chief financial officer now owns 454,420 shares in the company, valued at $1,867,666.20. This trade represents a 3.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP William Andrew Macan sold 12,175 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total transaction of $46,630.25. Following the completion of the sale, the executive vice president now directly owns 388,647 shares in the company, valued at approximately $1,488,518.01. This trade represents a 3.04 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 100,369 shares of company stock worth $358,929. 8.70% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Separately, Canaccord Genuity Group boosted their price target on shares of Neuronetics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th.
Check Out Our Latest Stock Report on Neuronetics
Neuronetics Company Profile
(
Get Free Report)
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Featured Stories
Before you consider Neuronetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neuronetics wasn't on the list.
While Neuronetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
